Anebulo Pharmaceuticals, Inc. (ANEB)

NASDAQ: ANEB · IEX Real-Time Price · USD
-0.03 (-0.71%)
Aug 10, 2022 3:58 PM EDT - Market closed

Company Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction.

Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Anebulo Pharmaceuticals, Inc.
Country United States
Founded 2020
IPO Date May 7, 2021
Industry Biotechnology
Sector Health Care
Employees 2

Contact Details

1415 Ranch Road 620 South
Lakeway, TX 78734
United States
Phone 512 598 0931

Stock Details

Ticker Symbol ANEB
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency US Dollars
IPO Price $7.00
CIK Code 1815974
ISIN Number US0345691036
SIC Code 2834

Key Executives

Name Position
Dr. Joseph F. Lawler M.D., Ph.D. Founder and Chairman
Rex Merchant CFA Chief Financial Officer
Simon J. Allen B.Sc., M.B.A., MBA Chief Executive Officer and Director
Dr. Kenneth C. Cundy Ph.D. Chief Scientific Officer
Scott L. Anderson Head of Investor Relations and Public Affairs

Latest SEC Filings

Date Type Title
Jul 5, 2022 8-K Current report
Jun 7, 2022 4 Statement of changes in beneficial ownership of securities
May 24, 2022 3 Initial statement of beneficial ownership of securities
May 24, 2022 8-K Current report
May 11, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 11, 2022 8-K Current report
Apr 21, 2022 S-8 Securities to be offered to employees in employee benefit plans
Apr 1, 2022 8-K Current report
Feb 11, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
Feb 11, 2022 8-K Current report